miRNA-143作为检测膀癌的潜在生物标志物:一个元分析
Jiajin Li1, Haonan Li1, Yutao Yang1
1Department of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
Future oncology (London, England)
|May 9, 2024
概括
微RNA-143显示出作为早期膀癌检测的非侵入性生物标志物的潜力. 这次系统性审查发现,它对识别膀癌 (BCa) 具有高灵敏度和特异性.
科学领域:
- 在瘤学瘤学.
- 生物标志物 生物标志物
- 分子诊断学 分子诊断
背景情况:
- 早期发现膀癌 (BCa) 对于改善患者的治疗结果至关重要.
- 目前的诊断方法可能具有侵入性或缺乏足够的灵敏度.
- 微RNAs (miRNAs) 正在成为各种癌症的有希望的生物标志物.
研究的目的:
- 系统地评估miRNA-143的诊断价值,用于早期检测膀癌 (BCa).
- 评估miRNA-143作为BCa.生物标志物的敏感性和特异性.
主要方法:
- 进行了系统性审查和元分析.
- 相关的数据库 (CNKI,WanFang,PubMed,威利在线图书馆) 进行了搜索.
- 使用随机效应模型将诊断准确度指标组合起来.
主要成果:
- 分析中包括了六项研究,共包括[参与者数量]的参与者.
- 在检测BCa时,miRNA-143的综合灵敏度为0.80 (95%CI:0.74-0.85).
- 聚合的特异性为0.85 (95% CI:0.78-0.91),其AUC为0.88 (95% CI:0.85-0.91).这些特异性中,AUC值为0.88 (95% CI:0.85-0.91).
- 与miR-100相结合,诊断功率 (AUC) 增加到0.95.
结论:
- miRNA-143显示出作为一种用于早期检测膀癌的非侵入性生物标志物的显著潜力.
- 它的高灵敏度和特异性表明它可以帮助临床诊断.
- 需要进一步的研究,在更大的队列中验证这些发现.
相关概念视频
MicroRNAs
21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K


